Job Trends
Oncternal Therapeutics will lay off about 10 workers as it explores “strategic alternatives” that could include asset sales or an M&A.
Labor Market Reports
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the second quarter of 2025, with increased pressure from further layoffs.
Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. Learn how strategic insights and targeted outreach can turn awareness into high-converting leads.
Now Hiring
Looking for a biopharma job in New York? Check out the BioSpace list of eight companies hiring life sciences professionals like you.
Of the 25 companies receiving tax incentives in Massachusetts, 23 will add jobs outside of Boston and Cambridge. Medtronic, which is receiving the largest award, will create 220 roles in Billerica. Other recipients include AbbVie, Dyne Therapeutics and Viridian Therapeutics.
Looking for a job in regulatory? Check out the BioSpace list of eight companies hiring life sciences professionals like you.
Career Advice
Here’s how smart prospective interviewees can optimally prepare for success in online interviews.
THE LATEST
Frontier Medicines will support the continued development of the company’s chemoproteomics drug discovery program, including lead asset, an inhibitor of KRASG12C.
BioNTech indicates the acquisition will add production capacity in support of U.S. clinical trials.
Regeneron continues to expand its presence in New York. Over the next six years, the company will invest approximately $1.8 billion to expand its Tarrytown facilities. The investment will support the addition of 1,000 new jobs.
There are two PDUFA dates on the U.S. Food and Drug Administration’s calendar for this week. Here’s a look.
In 2016, Mylan’s EpiPen became the flashpoint of drug pricing outrage when it became widely reported the life-saving drug had increased more than 400% in price over a period of seven years.
It was a moderately busy mid-summer week for clinical trial news. Here’s a look.
Master planning for the site is slated to begin in 2022 and will reportedly create one of the largest life sciences cluster in Europe.
Thermo Fisher Scientific continues to open new facilities that enable it to meet increasing manufacturing demands.
Thermo Fisher Scientific has launched a new collaborative unit that aims to standardize the metabolomics community’s efforts as it engages in more large-scale cohort studies and clinical research.
No specific financial details were disclosed other than to say the $1 billion figure was linked to various development and commercial milestones.